ProKidney
Business Services · North Carolina, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
2000 Frontis Plaza Blvd Ste 250, Winston...Phone Number
(336) 999-7019Website
www.prokidney.comRevenue
<$5 MillionStock Symbol
PROKIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
3
1
1
1
About ProKidney
ProKidney, founded in 2015, is an advanced biotechnology company focused on research and development of pioneering medical therapies. The company specializes in innovative treatments designed to transform the medical landscape, with a particular focus on kidney-related therapies. Based in North America, ProKidney operates in the biotech sector, combining scientific research with technological innovation to develop breakthrough medical solutions. The company maintains multiple locations and serves business clients in the healthcare industry.Explore more
ProKidney Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ProKidney your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
ProKidney, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once ProKidney has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if ProKidney has recently received funding, and reach out quickly before it becomes old news!
Click to see if ProKidney had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at ProKidney
Product Launch: Get notified when ProKidney launches new products
Earning: See what the market has to say on ProKidney recently announced quarterly report
Check out if ProKidney is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined ProKidney as Masked Content
Find 3 more new buyers
Compare Similar Companies to ProKidney
Compare insights from companies similar to ProKidney, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ProKidney is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ProKidney is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ProKidney.
ProKidney Tech Stack
A closer look at the technologies used by ProKidney
Most Recent Scoops
Project
ProKidney has designed the confirmatory approval endpoint of the Phase III PROACT 1 study as a composite time-to-event endpoint triggered after 122 events and including a 40% decline in eGFR, renal or cardiovascular death, sustained eGFR below 15, dialysis initiation, or kidney transplant powered at 80% with a hazard ratio assumption of 0.6, with a confirmatory readout expected in H2 2029.
Medical Research, Clinical Operations
Project
ProKidney has announced key upcoming milestones for its Phase III clinical program, including the completion of Phase III enrollment later in 2026, Phase III data for the surrogate endpoint of eGFR slope targeted for Q2 2027 to support accelerated approval, and a planned BLA submission in early 2028, with the company reporting it is funded through the Q2 2027 data readout.
Funding, Pharmaceuticals, Clinical Operations, Finance
New Hire
Executive Move
Executive Moves, New Hire
Person-Based
Earnings, Clinical Operations, Finance
Hiring Plans
Hiring Plans
ProKidney News & Media
ProKidney Appoints Kenneth Locke as Chief Technical Officer
Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencel Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencelProKidney Reports First Quarter 2026 Financial Results and Business Highlights
WINSTON-SALEM, N.C., May 15, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the first quarter ended March 31, 2026, and provided business highlights.What Makes ProKidney Corp. (PROK) So Attractive
ProKidney Corp. (NASDAQ:PROK) is one of the 10 best penny stocks that could triple your money. On March 19, ProKidney Corp. (NASDAQ:PROK) announced fourth-quarter revenue of $893,000 against consensus estimates of $600,000. The company provided updates on its clinical progress and strategic priorities for advancing rilparencel through regulatory pathways. Chief Executive Officer Bruce Culleton stated […]ProKidney hires chief commercial officer as key results near - Winston-Salem Journal
ProKidney Corp. announced Thursday it has named Greg Madison as its chief commercial officer. He is responsible for leading ProKidney’s commercial strategy as the company advances towards the potential commercialization
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding ProKidney
Sign Up For FreeTo access detailed company insights
ProKidney, founded in 2015, is an advanced biotechnology company focused on research and development of pioneering medical therapies. The company specializes in innovative treatments designed to transform the medical landscape, with a particular focus on kidney-related therapies. Based in North America, ProKidney operates in the biotech sector, com... Read More
